Premium
3 H‐thymidine uptake in B cell lymphomas — Relationship to treatment response and survival
Author(s) -
Kvaløy Stein,
Marton Per F.,
Kaalhus Olav,
Høie Johan,
FossAbrahamsen Arne,
Godal Tore
Publication year - 1985
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1985.tb00773.x
Subject(s) - thymidine , asymptomatic , gastroenterology , malignancy , medicine , biopsy , histopathology , stage (stratigraphy) , lymphoma , pathology , biology , dna , biochemistry , paleontology
Cell suspensions were obtained from biopsy tissue from 149 patients with B cell lymphomas and analysed with regard to DNA‐synthesis as assessed by 3 H‐thymidine uptake, response to therapy and survival. The 3 H‐thymidine uptake was significantly increased in lymphomas of high versus low grade malignancy (p = 0.0001), in patients with stage I and II versus stage III and IV (p = 0.014), and in patients with general symptoms (p = 0.0025) as opposed to asymptomatic cases. The complete response rate was significantly higher in patients with increased thymidine uptake than in those with low uptake, 26/51 (51%) cases versus 24/83 (29%) cases, respectively (p = 0.014). 55 patients with increased 3 H‐thymidine uptake survived for significantly shorter times than (94 patients) with low uptake (p = 0.0056). Furthermore, a markedly larger group of high‐risk patients was identified by the 3 H‐thymidine assay than by histopathology alone, 55 cases versus 23 cases, respectively. Among the patients (126 cases) with low grade tumours, those with increased 3 H‐thymidine uptake (40 cases) had poorer outcome than those with low uptake (86 cases) (p = 0.045). The data suggest that DNA‐synthesis in this study, as assessed by 3 H‐thymidine uptake, is an independent indicator of survival in NHL. Furthermore, it may be a useful parameter in laying down guidelines for therapy in B cell neoplasms, especially in low grade tumours.